CYPH
Cypherpunk TechnologiesยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
CYPH Profile
Cypherpunk Technologies Inc.
Research and Development of New Cancer Therapies and Digital Asset Treasury Layout Related to Zcash
47 Thorndike Street, Suite B1-1, Cambridge, MA 02141
--
Cypherpunk Technologies Inc., originally established as Dekkun Corporation on January 3, 2011, is a Delaware corporation. On November 13, 2025, the company changed its name to Cypherpunk Technologies Inc. The company is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat cancer patients by inhibiting basic tumor-promoting pathways, targeting cancer-specific cell surface molecules and using the immune system to attack cancer cells. Their strategy is to identify, acquire and develop molecules that will rapidly translate into high-impact treatments that produce long-lasting clinical benefits and improve patient outcomes. Their main clinical stage project is DKN-01, a monoclonal antibody that inhibits dickkopf-associated protein 1 (" DKK1 "). They are currently investigating the application of DKN-01 in patients with esophageal, gastric, gynecological or colorectal cancer in several ongoing clinical trials. Their second clinical stage project is FL -301, a monoclonal antibody against cells expressing Claudin 18.2 on the cell surface. They also have two preclinical antibody programs, FL-302 and FL-501.
